Lack of effect of enoximone on the pharmacokinetics of digoxin in patients with congestive heart failure. 1990

D Trenk, and F Hertrich, and B Winkelmann, and T Glauner, and H A Dieterich, and E Jähnchen
Department of Clinical Pharmacology, Rehabilitationszentrum, Bad Krozingen, Federal Republic of Germany.

The aim of this study was to investigate if the concomitant administration of the positive inotropic drug enoximone (100 mg tid) has any effect on the morning through levels of the cardiac glycoside digoxin in 17 patients with congestive heart failure (NYHA II-IV). Plasma concentrations of digoxin were 1.05 +/- 0.37 ng/mL before enoximone, 0.95 +/- 0.31 ng/mL at the end of the enoximone treatment period of 1 week and 0.95 +/- 0.36 ng/mL 1 week after cessation of enoximone treatment. Thus, concomitant administration of enoximone had no effect on plasma concentrations of digoxin while on the other hand the hemodynamics as assessed by NYHA-classification and determination of the heart volume improved significantly.

UI MeSH Term Description Entries
D007093 Imidazoles Compounds containing 1,3-diazole, a five membered aromatic ring containing two nitrogen atoms separated by one of the carbons. Chemically reduced ones include IMIDAZOLINES and IMIDAZOLIDINES. Distinguish from 1,2-diazole (PYRAZOLES).
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D004077 Digoxin A cardiotonic glycoside obtained mainly from Digitalis lanata; it consists of three sugars and the aglycone DIGOXIGENIN. Digoxin has positive inotropic and negative chronotropic activity. It is used to control ventricular rate in ATRIAL FIBRILLATION and in the management of congestive heart failure with atrial fibrillation. Its use in congestive heart failure and sinus rhythm is less certain. The margin between toxic and therapeutic doses is small. (From Martindale, The Extra Pharmacopoeia, 30th ed, p666) Digacin,Digitek,Digoregen,Digoxina Boehringer,Digoxine Nativelle,Dilanacin,Hemigoxine Nativelle,Lanacordin,Lanicor,Lanoxicaps,Lanoxin,Lanoxin-PG,Lenoxin,Mapluxin,Boehringer, Digoxina,Lanoxin PG,Nativelle, Digoxine,Nativelle, Hemigoxine
D005260 Female Females
D006333 Heart Failure A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION. Cardiac Failure,Heart Decompensation,Congestive Heart Failure,Heart Failure, Congestive,Heart Failure, Left-Sided,Heart Failure, Right-Sided,Left-Sided Heart Failure,Myocardial Failure,Right-Sided Heart Failure,Decompensation, Heart,Heart Failure, Left Sided,Heart Failure, Right Sided,Left Sided Heart Failure,Right Sided Heart Failure
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000369 Aged, 80 and over Persons 80 years of age and older. Oldest Old
D017335 Enoximone A selective phosphodiesterase inhibitor with vasodilating and positive inotropic activity that does not cause changes in myocardial oxygen consumption. It is used in patients with CONGESTIVE HEART FAILURE. Fenoximone,MDL 19438,MDL-17,043,MDL-17043,MDL-19,438,Perfan,MDL 17,043,MDL 17043,MDL 19,438,MDL17,043,MDL17043,MDL19,438

Related Publications

D Trenk, and F Hertrich, and B Winkelmann, and T Glauner, and H A Dieterich, and E Jähnchen
September 1987, Journal of clinical pharmacology,
D Trenk, and F Hertrich, and B Winkelmann, and T Glauner, and H A Dieterich, and E Jähnchen
April 1985, Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine,
D Trenk, and F Hertrich, and B Winkelmann, and T Glauner, and H A Dieterich, and E Jähnchen
April 1991, Journal of cardiovascular pharmacology,
D Trenk, and F Hertrich, and B Winkelmann, and T Glauner, and H A Dieterich, and E Jähnchen
January 1981, Journal of clinical pharmacology,
D Trenk, and F Hertrich, and B Winkelmann, and T Glauner, and H A Dieterich, and E Jähnchen
January 1989, European journal of clinical pharmacology,
D Trenk, and F Hertrich, and B Winkelmann, and T Glauner, and H A Dieterich, and E Jähnchen
September 2000, Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan,
D Trenk, and F Hertrich, and B Winkelmann, and T Glauner, and H A Dieterich, and E Jähnchen
January 1989, Journal of cardiovascular pharmacology,
D Trenk, and F Hertrich, and B Winkelmann, and T Glauner, and H A Dieterich, and E Jähnchen
July 1993, American journal of veterinary research,
D Trenk, and F Hertrich, and B Winkelmann, and T Glauner, and H A Dieterich, and E Jähnchen
January 1989, Clinical pharmacology and therapeutics,
D Trenk, and F Hertrich, and B Winkelmann, and T Glauner, and H A Dieterich, and E Jähnchen
September 1984, Journal of the American Geriatrics Society,
Copied contents to your clipboard!